Clinical trials: Norepinephrine
Septic Shock
Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock
We are performing a prospective, randomized, controlled trial of dopamine versus norepinephrine for septic shock. The trial will enroll patients with suspected or documented site of infection and having 2 out of the three SIRS…
- Trial name
- NCT00604019
- Testing
- Dopamine, Norepinephrine
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Rush University Medical Center
Anxiety Disorder
Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.
- Trial name
- NCT00114127
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Orthostatic Hypertension
Intravenous Norepinephrine for Orthostatic Hypotension
Background: Orthostatic hypotension is a fall in blood pressure when standing up. Normally, a reflex action of the automatic nervous system makes blood vessels tighten when people stand up.
- Trial name
- NCT01285908
- Testing
- Intravenous Norepinephrine Infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and…
- Trial name
- NCT04144257
- Testing
- [F-18]PBR06, [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Alcoholism
Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.
- Trial name
- NCT02966340
- Testing
- Prazosin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Dysautonomia, Familial, Baroreflex Failure Syndrome
Carbidopa for the Treatment of Excessive Blood Pressure Variability
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated…
- Trial name
- CarbiFD (NCT02553265)
- Testing
- Carbidopa Low-Dose, Carbidopa High-Dose
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- NYU Langone Health
Alcoholism
Testing Doxazosin to Treat Stress Mechanisms in Alcoholism
Double-blind, placebo controlled, randomized controlled trial (RCT) for Alcohol Use Disorder examining the effects of doxazosin, a norepinephrine alpha1 receptor antagonist, on stress reactivity and clinical outcomes.
- Trial name
- NCT02989493
- Testing
- Doxazosin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Wisconsin, Madison
Hypotension, Orthostatic, Hypotension
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
The goal of this study is to determine the efficacy of the drug Droxidopa (Northera) in increasing blood pressure in subject with hypotension, low blood pressure, which is classified as blood pressure less than 110/70 in males…
- Conditions
- Hypotension, Orthostatic, Hypotension, Spinal Cord Injuries
- Trial name
- NCT03602014
- Testing
- Northera
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Attention Deficit Hyperactivity Disorder
Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder
The aims of the current study are to examine gene-environment interactions associated with norepinephrine (NE) system genes (ADRA2A, SLC6A2) in ADHD, and to evaluate whether genetic changes in norepinephrine pathway are…
- Trial name
- NCT01912352
- Testing
- Methylphenidate
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Seoul National University
Parkinson Disease
Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
The purpose of this study is to find out whether droxidopa, a medication that increases norepinephrine levels, may be effective in improving some aspects of cognition and movement in Parkinson's disease (PD).
- Trial name
- NCT03115827
- Testing
- Droxidopa, Carbidopa
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University Medical Center
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Depression, Major Depressive Disorder
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
- Trial name
- GEMINI (NCT04019704)
- Testing
- AXS-05
- Where
- 43 sites in United States
- Volunteers
- 327 people
- Sponsor
- Axsome Therapeutics, Inc.
Septic Shock
High MAP in Septic Shock With Hypertension
We hypothesized that the increase in MAP from 65 mmHg to patients' usual level improved sublingual microcirculation.
- Trial name
- NCT01443494
- Testing
- NE
- Where
- China
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Southeast University, China
General Anxiety Disorder, Social Anxiety Disorder
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder
This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment.
- Trial name
- NCT00411398
- Testing
- Namenda/Memantine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Cardiac Disease
Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:
The relative increase in the mPAP with the same unit increase in MAP adjusted for baseline, and RV function assessed by GLS, between VP and NE in patients with normal and increased pulmonary artery pressure, who require…
- Trial name
- NCT04501861
- Testing
- Vasopressin, Norepinephrine
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- The Cleveland Clinic
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
Primary Fibromyalgia
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
- Trial name
- MyFi (NCT01331109)
- Testing
- Milnacipran
- Where
- 31 sites in United States
- Volunteers
- 57 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
This study aims to test the effect of a newly-approved stimulant medication, lisdexamfetamine dimesylate (Vyvanse), on specific residual symptoms of depression found in some patients who are undergoing treatment with, but have…
- Trial name
- NCT01148979
- Testing
- Lisdexamfetamine Dimesylate (Vyvanse)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mclean Hospital
Sexual Dysfunctions, Psychological, Depression
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
The current trial will explore the safety of flibanserin in combination with Selective Serotonin Reuptake Inhibitors or Norepinephrine Serotonin Reuptake Inhibitors in a representative population of women with depressive and…
- Trial name
- NCT01040208
- Testing
- flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs
- Where
- 42 sites in United States
- Volunteers
- 111 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma